Market Size of Global Uveitis Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Uveitis Treatment Market Analysis
The Uveitis Treatment market will show rapid growth due to the increasing cases of uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.
The market for uveitis treatment is expected to be affected by the COVID - 19 outbreak which is majorly attributed to the lockdown being followed by major countries. Disrupted the supply chain had a direct impact on the market studied as many drugs could not reach the market on time. Uveitis patients are potentially at higher risk of exposure to infections including COVID-19. These above-mentioned elements are expected to burden the revenue trajectory of the global Uveitis Treatment market over the forecast period. However, as respective governing authorities have lifted these enforced lockdowns, the global Uveitis Treatment market is expected to recover accordingly.
The increasing prevalence of optical infections and chronic eye disorders across the globe represents is one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy, and autoimmune and inflammatory disorders. Furthermore, the market is being driven by the growing senior population, which is more sensitive to such disorders. If measures are not taken properly, these diseases can easily spread through human touch (through hands, clothes, or bedding) and by flies that have to meet discharges from an infected person's eyes or nose. In September 2021, a Non-profit group, Prevent Blindness, conducted awareness campaign on various forms of Inflammatory Eye Diseases (IED). In October 2021, ABIONYX Pharma announced the positive pre-clinical results for ER-001 in uveitis treatment and the development of first-class of biomedicines from its bio-HDL for the treatment of ocular pathologies. Thus, the government initiatives for the management of eye pathologies and rising R&D activities for the development of new therapies are some of the significant factors expected to drive the market growth.
Moreover, Trachoma is a disease of the eye caused by infection with the bacterium Chlamydia trachomatis. In March 2020, according to data published by World Health Organization (WHO), around 137 million people live in trachoma endemic areas and are at risk of trachoma blindness. Therefore, the high and increasing prevalence rate of these infectious diseases resulted in the increasing awareness regarding the available alternative treatments for managing uveitis are anticipated to drive the market further. Moreover, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors.
Uveitis Treatment Industry Segmentation
As per the scope of this report uveitis treatment refers to various remedies for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of the eye, and sensitivity to light. The Uveitis Treatment Market is segmented By Treatment (Corticosteroids, Antibiotics, Antivirals, Antifungal, Analgesics, and Others), By Disease (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD billion) for the above segments.
| By Treatment | |
| Corticosteroids | |
| Antibiotics | |
| Antivirals | |
| Antifungal | |
| Analgesics | |
| Others |
| By Disease | |
| Anterior Uveitis | |
| Posterior Uveitis | |
| Intermediate Uveitis | |
| Panuveitis |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Uveitis Treatment Market Size Summary
The uveitis treatment market is poised for significant expansion, driven by the rising incidence of uveitis and advancements in drug development. The market's growth trajectory is supported by an increasing prevalence of optical infections and chronic eye disorders, particularly among populations with diabetes, eye injuries, and autoimmune conditions. The aging demographic, more susceptible to such disorders, further propels market demand. Government initiatives and awareness campaigns, alongside ongoing research and development efforts, are crucial in managing eye pathologies and fostering the introduction of innovative therapies. Technological advancements, including non-steroidal injectables and anti-tumor necrosis factor drugs, are also contributing to the market's growth. Corticosteroids remain the dominant treatment option due to their efficacy in controlling inflammation, although biological therapies are under exploration.
The North American region leads the market, attributed to the high prevalence of uveitis in the United States and robust research and development activities. The market is characterized by intense competition, with major players like AbbVie, Novartis, and Bausch Health Inc. holding significant market shares. The introduction of new treatments, such as adalimumab injectable biosimilars and injectable suspensions, underscores the dynamic nature of the market. Despite challenges posed by the COVID-19 pandemic, which disrupted supply chains and impacted market growth, the market is expected to recover as restrictions ease. The ongoing development of therapies and strategic expansions by key players are anticipated to sustain the market's momentum in the coming years.
Global Uveitis Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Incidence of Uveitis and its Complications
-
1.2.2 Rising Expenditure on the Research and Development of New Drugs and Treatments
-
-
1.3 Market Restraints
-
1.3.1 Steep Prices of Medications and Side Effects of The Medication
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Treatment
-
2.1.1 Corticosteroids
-
2.1.2 Antibiotics
-
2.1.3 Antivirals
-
2.1.4 Antifungal
-
2.1.5 Analgesics
-
2.1.6 Others
-
-
2.2 By Disease
-
2.2.1 Anterior Uveitis
-
2.2.2 Posterior Uveitis
-
2.2.3 Intermediate Uveitis
-
2.2.4 Panuveitis
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Uveitis Treatment Market Size FAQs
What is the current Global Uveitis Treatment Market size?
The Global Uveitis Treatment Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Global Uveitis Treatment Market?
Bausch Health Inc. , AbbVie Inc. , Eyegate Pharmaceuticals, Inc., Clearside Biomedical inc. and EyePoint Pharmaceuticals are the major companies operating in the Global Uveitis Treatment Market.
